Small molecule · Inhibitor of DNA polymerase theta (pol theta) helicase domain (POLQ) · developed by ASTRAZENECA
AZD4956 is an orally bioavailable inhibitor that binds the helicase domain of DNA polymerase theta, blocking theta-mediated end joining repair of DNA double-strand breaks. It is being studied in solid tumours, particularly homologous recombination-deficient cancers that depend on this repair pathway.
Summary written with AI from the sources listed at the end of this page.
Solid Tumours
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →